Ticagrelor
Segment Elevation Myocardial Infarction (STEMI)
AstraZenecaSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Segment Elevation Myocardial Infarction (STEMI) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Plavix IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Acetylsalicylic Acid St. Antonius Hospital | Phase 4 | BB |
Dabigatran IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Rivaroxaban IHF GmbH - Institut für Herzinfarktforschung | Phase 4 | BB |
Tenecteplase AO GENERIUM | Phase 3 | B |
Gnr-060 AO GENERIUM | Phase 3 | B |
Alirocumab Population Health Research Institute | Phase 2 | B |
Same molecule, other indications
Ticagrelor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →